Skip to content

Study · Randomized controlled trial · n = 146 · 2005

6 results

Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial.

Ladurner G, Kalvach P, Moessler H

Journal of neural transmission (Vienna, Austria : 1996)7 Dec 2004Cited by 61 (Europe PMC)

PMID15583955 (opens in a new tab)DOI10.1007/s00702-004-0248-2 (opens in a new tab)PepBankPUB-15583955
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with acute stroke, Cerebrolysin did not significantly improve Canadian Neurological Scale scores versus placebo.

    In plain wordsIn patients with acute stroke, Cerebrolysin did not significantly improve neurological scores compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeCanadian Neurological Scale
    Study

    n = 146

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 mL/day · IV · 21 daysAs given in this study (human).

    Source sentences

    Summary
    Patients in the Cerebrolysin group had no significant improvement in the CNS score, the Barthel Index and the Clinical Global Impressions when compared to the placebo group.
    4 context sentences
    Summary · context
    Outcome measures were the Canadian Neurological Scale, the Barthel Index, the Clinical Global Impressions, the Mini-Mental State Examination, and the Syndrome Short Test.
    Summary · context
    Randomised, placebo-controlled, parallel group trial.
    Summary · context
    Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days.
    Summary · context
    Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with acute stroke, Cerebrolysin did not significantly improve the Barthel Index versus placebo.

    In plain wordsIn patients with acute stroke, Cerebrolysin did not significantly improve daily-function scores compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeBarthel Index
    Study

    n = 146

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 mL/day · IV · 21 daysAs given in this study (human).

    Source sentences

    Summary
    Patients in the Cerebrolysin group had no significant improvement in the CNS score, the Barthel Index and the Clinical Global Impressions when compared to the placebo group.
    3 context sentences
    Summary · context
    Randomised, placebo-controlled, parallel group trial.
    Summary · context
    Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days.
    Summary · context
    Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with acute stroke, Cerebrolysin did not significantly improve Clinical Global Impressions versus placebo.

    In plain wordsIn patients with acute stroke, Cerebrolysin did not significantly improve overall clinical ratings compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeClinical Global Impressions
    Study

    n = 146

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 mL/day · IV · 21 daysAs given in this study (human).

    Source sentences

    Summary
    Patients in the Cerebrolysin group had no significant improvement in the CNS score, the Barthel Index and the Clinical Global Impressions when compared to the placebo group.
    3 context sentences
    Summary · context
    Randomised, placebo-controlled, parallel group trial.
    Summary · context
    Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days.
    Summary · context
    Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with acute stroke, Cerebrolysin significantly improved cognitive function on the Syndrome Short Test versus placebo.

    In plain wordsIn patients with acute stroke, Cerebrolysin improved cognition on the Syndrome Short Test compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseSyndrome Short Test cognitive function
    Study

    n = 146

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    50 mL/day · IV · 21 daysAs given in this study (human).

    Source sentences

    Summary
    A significant improvement of cognitive function of the patients on Cerebrolysin was observed in the Syndrome Short Test when compared to the placebo group.
    3 context sentences
    Summary · context
    Randomised, placebo-controlled, parallel group trial.
    Summary · context
    Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days.
    Summary · context
    Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV.
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with acute stroke, adverse events occurred at similar frequencies with Cerebrolysin and placebo.

    In plain wordsIn patients with acute stroke, adverse events occurred at similar frequencies with Cerebrolysin and placebo.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeAdverse-event frequency
    Study

    n = 146

    Comparator
    Placebo
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    50 mL/day · IV · 21 daysAs given in this study (human).

    Source sentences

    Summary
    Adverse events occurred with a similar frequency in both groups.
    3 context sentences
    Summary · context
    Randomised, placebo-controlled, parallel group trial.
    Summary · context
    Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days.
    Summary · context
    Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with acute stroke, Cerebrolysin was reported as well tolerated and safe.

    In plain wordsIn patients with acute stroke, Cerebrolysin was reported as well tolerated and safe.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableTolerability
    Study

    n = 78

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    50 mL/day · IV · 21 daysAs given in this study (human).

    Source sentences

    Summary
    Cerebrolysin was well tolerated and safe.
    3 context sentences
    Summary · context
    Randomised, placebo-controlled, parallel group trial.
    Summary · context
    Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days.
    Summary · context
    Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.